Application of protein polymer in treatment of gradual freezing
By using a variety of human protein polymers to reduce the concentration of TDP-43 protein in cerebrospinal fluid, the problem of ALS treatment was solved, significantly prolonging the survival of mice, improving motor function, and showing improved symptoms in clinical trials Effect.
Patent Information
- Application Number
- CN202410945391.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-03-19
- Filing Date
- 2024-07-15
- Publication Date
- 2024-11-08
AI Technical Summary
There is currently a lack of effective treatment options to alleviate or cure ALS (amyotrophic lateral sclerosis), especially due to the diverse early clinical manifestations and the lack of specific biological diagnostic indicators, which leads to difficulty in diagnosis and treatment.
A protein polymer is used to treat A. a protein polymer by reducing the concentration of TDP-43 protein in cerebrospinal fluid and increasing the concentration of TDP-43 protein in the serum. The protein polymer includes a variety of human proteins, such as serum protein, transferrin, photolink protein, etc., which are used to reduce the concentration of TDP-43 protein through specific preparation methods and administration methods to relieve symptoms.
It was shown that it could significantly prolong the survival of SOD1 mutant mice, improve motor function, slow muscle atrophy, reduce cerebrospinal fluid concentration of TDP-43 protein, and improve ALSFRS-R in patients with ALSFRS-R and Norris scores to prolong the course of the disease.
Smart Images

Figure CN118903378A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and specifically relates to an application of a protein polymer in treating amyotrophic lateral sclerosis. Background Art
[0002] Amyotrophic lateral sclerosis (ALS) is the most common type of motor neuron disease. It is more common in middle-aged and elderly people. The peak age of ALS in my country is around 50 years old, and the age of onset tends to be younger. A few patients may develop the disease at around 20 years old. The main clinical manifestations are progressive skeletal muscle weakness, atrophy, fasciculations, bulbar palsy and pyramidal tract signs. Some ALS patients may have varying degrees of cognitive and (or) behavioral disorders and other manifestations of frontal and temporal lobe involvement. About 10% of ALS patients are familial, and multiple genes have been found to be associated with it. The early clinical manifestations of ALS are diverse, and there is a lack of specific biological diagnostic indicators. In the clinical diagnosis process, determining the scope of upper and lower motor neuron involvement is a key step in diagnosis. According to the anatomical location of the patient's symptoms and signs, the affected area is usually divided into four areas: brainstem, cervical, thoracic and lumbar sacral.
[0003] Affected by genetic factors, lifestyle, work pressure and other factors, the number of ALS patients is increasing and the onset is at a younger age, but there is currently no satisfactory treatment option. The field urgently needs to develop new drugs and methods that are effective in treating or alleviating ALS. Summary of the invention
[0004] The purpose of the present invention is to overcome at least one deficiency of the prior art and provide a protein polymer for use in treating ALS.
[0005] The technical solution adopted by the present invention is:
[0006] A use of a protein polymer in the treatment of amyotrophic lateral sclerosis, wherein the protein polymer is used to reduce the concentration of TDP-43 protein in cerebrospinal fluid and increase the concentration of TDP-43 protein in serum.
[0007] In some embodiments, the protein polymer comprises at least the following proteins:
[0008] sp|P02768|ALBU_HUMAN Serum albumin OS=Homo sapiens;
[0009] sp|P02787|TRFE_HUMAN Serotransferrin OS=Homo sapiens.
[0010] In some embodiments, the protein polymer further comprises at least one of the following proteins:
[0011] sp|P51884|LUM_HUMAN Lumican OS=Homo sapiens;
[0012] sp|P62736|ACTA_HUMAN Actin,aortic smooth muscle OS=Homo sapien;
[0013] sp|P01009|A1AT_HUMAN Alpha-1-antitrypsin OS=Homo sapiens;
[0014] sp|P07951|TPM2_HUMAN Tropomyosin beta chain OS=Homo sapiens;
[0015] sp|P08670|VIME_HUMAN Vimentin OS=Homo sapiens;
[0016] sp|P02751|FINC_HUMAN Fibronectin OS=Homo sapiens;
[0017] sp|P09493|TPM1_HUMAN Tropomyosin alpha-1chain OS=Homo sapiens;
[0018] sp|P21333|FLNA_HUMAN Filamin-A OS=Homo sapiens;
[0019] sp|P0DOX5|IGG1_HUMAN Immunoglobulin gamma-1heavy chain OS=Homosapiens;
[0020] sp|P24821|TENA_HUMAN Tenascin OS=Homo sapiens;
[0021] sp|P01023|A2MG_HUMAN Alpha-2-macroglobulin OS=Homo sapiens;
[0022] sp|P60709|ACTB_HUMAN Actin,cytoplasmic 1OS=Homo sapiens;
[0023] sp|P69891|HBG1_HUMAN Hemoglobin subunit gamma-1OS=Homo sapiens;
[0024] sp|P01024|C3 HUMAN Complement C3 OS=Homo sapiens.
[0025] In some embodiments, the sum of the masses of sp|P02768|ALBU_HUMAN Serum albumin OS=Homo sapiens and sp|P02787|TRFE_HUMAN Serotransferrin OS=Homo sapiens in the protein polymer accounts for more than 40% of the total mass.
[0026] In some embodiments, the preparation of the above protein polymer comprises the following steps:
[0027] S1: Cultivating mesenchymal stem cells and using ultraviolet irradiation to create a stress environment;
[0028] S2: Lysing the mesenchymal stem cells, separating and purifying to obtain protein polymers.
[0029] In some embodiments, the protein polymer satisfies at least one of the following properties:
[0030] 1) During the molecular sieve exclusion chromatography, under the conditions of the exclusion chromatography with a flow rate of 0.1-0.3 ml / min and the eluent being PBS, the elution volume of the first component peak was 12-13.2 ml, the elution volume of the second component peak was 15.2-17 ml, the elution volume of the third component peak was 17-20 ml, the elution volume of the fourth component peak was 29-31 ml, and the elution volume of the fifth component peak was 31-34 ml;
[0031] 2) During SDS-PAGE detection, 4-20% precast gel was used for sample separation and detection. The sample bands were mainly distributed in the range of 11KD to 100KD, and the molecular weight was from large to small. The first band was located between 75KD and 100KD; the second band was located between 63KD and 75KD;
[0032] 3) In reverse phase HPLC detection, the sample volume is 80-120 μL, the column temperature is 20-30° C., the flow rate is 0.2-0.8 mL / min, the detection wavelength is 260 nm and / or 280 nm, the mobile phase is PBS solution, and the peak time after sample separation is between 10 and 40 min, among which the peak time of characteristic peak 1 is 13-17 min, and the peak time of characteristic peak 2 is 20-22 min.
[0033] In some embodiments, the duration of ultraviolet irradiation is 1 to 30 hours; and / or the intensity of ultraviolet irradiation is 10 to 100 μW / cm 2 ; and / or, the wavelength of ultraviolet light is 290 to 340 nm.
[0034] In some embodiments, the culture medium used is a serum-free MSCs culture medium.
[0035] In some embodiments, the mesenchymal stem cells are selected from one of umbilical cord-derived human mesenchymal stem cells, bone marrow-derived mesenchymal stem cells, and human placenta-derived mesenchymal stem cells.
[0036] In some embodiments, the protein polymer is administered by a route selected from intrathecal administration, intravenous administration, or a combination of intrathecal and intravenous administration. BRIEF DESCRIPTION OF THE DRAWINGS
[0037] Figure 1 This is a photograph of the cell state after irradiation in Example 1.
[0038] Figure 2 It is the SDS-PAGE electrophoresis picture of the protein harvested in Example 1.
[0039] Figure 3 This is the elution curve of Example 2.
[0040] Figure 4 It is the SDS-PAGE electrophoresis diagram of sample No. 12 (pure-12#) after purification in Example 3.
[0041] Figure 5 This is the elution curve of Example 3.
[0042] Figure 6 and Figure 7 The effects of different treatments on the anterior horn motor neurons of the spinal cord of SOD1 mutant mice.
[0043] Figure 8 and Fig. 9 The effects of different treatments on the gastrocnemius muscle of SOD1 mutant mice.
[0044] Fig.10 These are the experimental results of the rotarod test on SOD1 mutant mice subjected to different treatments.
[0045] Fig.11 and Fig.12 The effect of different treatments on the survival of SOD1 mutant mice.
[0046] Figure 13-Figure 15 These are the ALSFRS-R and Norris score results from a clinical trial of ALS patients.
[0047] Fig.16 These are the test results of TDP-43 in the cerebrospinal fluid of ALS patients. DETAILED DESCRIPTION
[0048] The technical solution of the present invention is further described below in conjunction with embodiments.
[0049] Example 1: Cultivation of human umbilical cord mesenchymal stem cells
[0050] Resuscitate a small crystal of P8 HUC-MSC (human umbilical cord mesenchymal stem cells) into a T25 culture flask and add 2.5 ml of Huakai mesenchymal stem cell serum-free culture medium.
[0051] The cells were irradiated with 300nm LED UV for 6h. The cells were carefully cleaned of supernatant, washed twice with 1ml physiological saline, added with 660μl pure water and repeatedly blown for 10min, filtered through a 0.22um filter membrane, and stored at 4℃.
[0052] UV irradiation conditions are as follows:
[0053] Intermediate medium T25 bottle <![CDATA[UVA(μW / cm 2 )]]> 11.71 <![CDATA[UVB(μW / cm 2 )]]> 26.81 Peak wavelength (nm) 320.4
[0054] The cell status after irradiation is Figure 1 The protein polymer stock solution (also called Aleeto or ALT) was harvested, with a protein concentration of 0.718 mg / ml and a volume of 500 μl. The SDS-PAGE results of the harvested protein are shown in Figure 2 shown.
[0055] Example 2: Molecular sieve purification and activity detection of protein polymers
[0056] 2-1 Molecular sieve purification of protein polymers:
[0057] Instrument: AKTA explorer
[0058] Chromatographic column: Nano-micron superdex150 molecular sieve 8×500, column volume is about 30mL
[0059] Reagents: 0.1M NaOH, 20% ethanol, 1× PBS, purified water
[0060] UV absorption wavelength: 280nm, 260nm as reference
[0061] Equilibration column sequence:
[0062] The column was first rinsed with 2CV of pure water, and then equilibrated with 1×PBS for 2CV, and the UV absorption value at 280nm was returned to zero.
[0063] Sample preparation: Repeat the method in Example 1 to harvest a total of 20 mL of protein. Use an ultrafiltration concentration tube with a molecular weight cutoff of 3 KD to reduce the 20 mL sample to about 600 μl.
[0064] Experimental process: After balancing the column, select a 500μl sample loop for sample loading, the sample loading flow rate is 0.4mL / min, the 1×PBS elution flow rate is 0.2mL / min, and the elution is performed until the peak. Collect the protein, starting from the UV absorbance value of 4mAU. For details of the elution curve, see Figure 3 .Pick Figure 3 The proteins at positions 2, 9, 12, 16, and 18 are freeze-dried and stored.
[0065] 2-2 Biological Activity Detection of Protein Aggregates
[0066] Day 1: Cell plating: Complete medium (5% FBS + DMEM) was used to dilute PC12 poorly differentiated cells, and 6,000 cells were plated per well (96-well plate). Incubate at 37°C with 5% CO2 overnight.
[0067] The next day: Lyophilized samples and samples before purification were diluted with DMEM+5% FBS medium (about 800 μg / ml).
[0068] Take 30% hydrogen peroxide and dilute it 15,000 times with DMEM + 5% FBS.
[0069] Hydrogen peroxide treatment: discard 80 μL / well culture supernatant of cells, add 50 μL / well diluted hydrogen peroxide to the corresponding cultured cells, and place at room temperature for 25 minutes.
[0070] Untreated control: 50 μL / well of DMEM+5% FBS medium was added as the injury treatment control.
[0071] 50 μL / well of the diluted sample was added to the wells treated with hydrogen peroxide.
[0072] The supernatant of the untreated wells was discarded, and 100 μL / well of complete culture medium was added as a cell growth control (PC).
[0073] Incubate at 37°C for 2 days.
[0074] Day 5: Discard the culture supernatant, add complete culture medium at 100 μL / well, set up a culture medium blank control well, add CCK8 at 10 μL / well, and incubate at 37°C for 3.5 h. OD 450 Read the value and calculate after subtracting the culture medium blank.
[0075] The experimental results are shown in Table 1.
[0076] Table 1 Biological activity experimental data of different samples
[0077]
[0078] As shown in Table 1, in the PC12 cell oxidative damage model, samples 2#, 12#, and 16# all have strong oxidative damage repair capabilities, and their repair capabilities are better than those of unpurified samples. The repair ability of sample 18# is lower than that of the unpurified sample.
[0079] The purified 12# sample was subjected to SDS-PAGE electrophoresis analysis. The electrophoresis results were as follows: Figure 4 As shown in the figure, the sample bands are mainly distributed between 11KD and 100KD, and the molecular weight is from large to small. The first band is between 75KD and 100KD; the second band is between 63KD and 75KD. Further analysis shows that the purified protein polymer includes the following proteins:
[0080] sp|P02768|ALBU_HUMAN Serum albumin OS=Homo sapiens;
[0081] sp|P02787|TRFE_HUMAN Serotransferrin OS=Homo sapiens.
[0082] The above two are the main proteins, accounting for more than 40% of the total mass of protein polymers. Other proteins include:
[0083] sp|P51884|LUM_HUMAN Lumican OS=Homo sapiens;
[0084] sp|P62736|ACTA_HUMAN Actin, aortic smooth muscle OS=Homo sapiens;
[0085] sp|P01009|A1AT_HUMAN Alpha-1-antitrypsin OS=Homo sapiens;
[0086] sp|P07951|TPM2_HUMAN Tropomyosin beta chain OS=Homo sapiens;
[0087] sp|P08670|VIME_HUMAN Vimentin OS=Homo sapiens;
[0088] sp|P02751|FINC_HUMAN Fibronectin OS=Homo sapiens;
[0089] sp|P09493|TPM1_HUMAN Tropomyosin alpha-1chain OS=Homo sapiens;
[0090] sp|P21333|FLNA_HUMAN Filamin-A OS=Homo sapiens;
[0091] sp|P0DOX5|IGG1_HUMAN Immunoglobulin gamma-1heavy chain OS=Homosapiens;
[0092] sp|P24821|TENA_HUMAN Tenascin OS=Homo sapiens;
[0093] sp|P01023|A2MG_HUMAN Alpha-2-macroglobulin OS=Homo sapiens;
[0094] sp|P60709|ACTB_HUMAN Actin,cytoplasmic 1OS=Homo sapiens;
[0095] sp|P69891|HBG1_HUMAN Hemoglobin subunit gamma-1OS=Homo sapiens;
[0096] sp|P01024|C3 HUMAN Complement C3 OS=Homo sapiens.
[0097] Example 3: HPLC-SEC purification and protein polymer activity detection
[0098] Based on the difference in hydrophobicity, reverse phase chromatography can be used to separate the protein polymers obtained by ultraviolet irradiation stimulation of the present invention. Under initial conditions, the concentration of organic components in the mobile phase is low, the hydrophobic interaction between the protein polymer and the stationary phase is strong, and the protein polymer is almost completely adsorbed by the stationary phase; when the organic components in the mobile phase reach a specific concentration, the protein polymer is completely eluted from the stationary phase and no longer interacts with the stationary phase. Therefore, a very small change in the organic components of the mobile phase can significantly affect the reverse phase retention behavior of the protein polymer.
[0099] 3-1 HPLC-SEC purification
[0100] Test product information: The protein polymer (ALEETO stock solution) prepared by the method of Example 1 was diluted to 1 mg / ml with PBS.
[0101] Mobile phase: PBS
[0102] Detection conditions: injection volume 100 μL, column temperature 25°C, flow rate 0.4 ml / min, wavelength 280 nm, 260 nm; time: 48 min
[0103] The collection time range is approximately: 1#13.3~14.5min; 2#21.5~22min; 3#22~22.8min; 4#23~23.7min; 5#26.8~27.8min; 6#27.8~28.7min; 7#28.7~30min; 8#30~30.6min; 9#30.6~32 (no obvious peak of A280)min; 10#33.8~34.8min.
[0104] The elution curve is Figure 5 As shown, the proteins at positions 1-10 shown in the figure are taken and freeze-dried for storage.
[0105] 3-2 Biological Activity Detection of Protein Polymers
[0106] Day 1: Cell plating: Complete medium (5% FBS + DMEM) was used to dilute PC12 poorly differentiated cells, and 6,000 cells were plated per well (96-well plate). Incubate at 37°C with 5% CO2 overnight.
[0107] The next day: the lyophilized sample and the sample before purification were diluted with DMEM+5% FBS medium (about 800ug / ml).
[0108] Take 30% hydrogen peroxide and dilute it 15,000 times with DMEM + 5% FBS.
[0109] Hydrogen peroxide treatment: discard 80 μL / well culture supernatant of cells, add 50 μL / well diluted hydrogen peroxide to the corresponding cultured cells, and place at room temperature for 25 minutes.
[0110] Untreated control: 50 μL / well of DMEM+5% FBS medium was added as the injury treatment control.
[0111] 50 μL / well of the diluted sample was added to the wells treated with hydrogen peroxide.
[0112] The supernatant of the untreated wells was discarded, and 100 μL / well of complete culture medium was added as a cell growth control (PC).
[0113] Incubate at 37°C for 2 days.
[0114] Day 5: Discard the culture supernatant, add complete culture medium at 100 μL / well, set up a culture medium blank control well, add CCK8 at 10 μL / well, and incubate at 37°C for 3.5 h. OD 450Read the value and calculate after subtracting the culture medium blank.
[0115] The experimental results are shown in Table 2.
[0116] Table 2 Biological activity experimental data of different samples
[0117]
[0118] As shown in Table 2, in the PC12 cell oxidative damage model, samples 1#, 2#, 7#, 8#, and 10# all have strong oxidative damage repair capabilities, and their repair capabilities are better than those of the samples before purification. The repair ability of sample 5# is lower than that of the sample before purification.
[0119] Example 4: Application of the present invention in treating ALS
[0120] The protein polymer obtained in Example 1 of the present invention (also referred to as Aleeto, abbreviated as Aleeto or ALT) is used below to further study its application in the treatment of ALS.
[0121] 4-1 Experiments on SOD1 mutant mice
[0122] The effects of the protein polymer of the present invention on the motor dysfunction of SOD1 mutant mice were studied using 100-day-old ALS model SOD1G93A mice (referred to as SOD1 mutant mice). The SOD1 mutant mice were used as the model control group and the experimental group, and the 100-day-old C57BL / 6J mice were used as the normal control group, with 10 mice in each group.
[0123] The model control group was not given any medication, while the experimental group was given Alito and Riluzole. Alito was given by intrathecal administration, intravenous administration, and combined intrathecal and intravenous administration, while Riluzole was given by gavage. The medication cycle was 14 days.
[0124] See also Figure 6 and Figure 7 , SOD1 mutant mice (model control group, SOD1 G93A ) The number of motor neurons in the anterior horn of the spinal cord was significantly less than that in the wild-type control (normal control group, WT). After treatment with 60μg / kg alituo by intrathecal administration (it), intravenous administration (iv), and combined administration (i.t+iv), the number of motor neurons increased significantly and was close to that of the wild-type. Riluzole treatment was slightly better than intrathecal alituo, but inferior to the other two administration methods.
[0125] See also Figure 8 and Fig. 9 , SOD1 mutant mice (model control group, SOD1 G93A) The gastrocnemius muscles were severely atrophied, and the muscle cross-sectional area was significantly smaller than that of the wild-type control (normal control group, WT). After treatment with different doses of alitoxan combined with 20 μg / kg of alitoxan (SOD1 G93A +20μg / kg i.t+iv) had the best effect. Riluzole treatment failed to significantly improve muscle atrophy.
[0126] See also Fig.10 The rotarod test was used to reflect the motor ability of mice: with the increase of age, SOD1 mutant mice (SOD1 G93A ) gradually decreased the time they stayed on the rotating rod, indicating a progressive loss of motor function. After treatment with different doses of alitox, the decline in the mice's motor ability was significantly attenuated, with 20 μg / kg of alitox (SOD1 G93A +ALT 20μg / kg i.t+iv) had the best effect. Riluzole treatment failed to significantly improve the motor ability of mice.
[0127] See also Fig.11 Compared with wild-type mice (WT), SOD1 mutant mice (SOD1 G93A ) significantly shortened their survival. After different doses of alitoxan combined with other drugs, the survival of mice was significantly prolonged. G93A +ALT 20μg / kg i.t+iv) has the best effect. Fig.12 , Riluzole could not prolong the survival of mice.
[0128] 4-2 Clinical Trials
[0129] See also Fig.13 A clinical experiment was conducted using the protein polymer stock solution in Example 1 on 7 ALS patients in Hospital A and 2 ALS patients in Hospital B.
[0130] 4-2-1 Selection Criteria
[0131] 1. Patients diagnosed with amyotrophic lateral sclerosis (ALS) after taking the drug;
[0132] 2. Each item of the modified amyotrophic lateral sclerosis functional rating scale (ALSFRS-R) is ≥ 2 points (including dyspnea, orthopnea and respiratory insufficiency, which must all be 4 points);
[0133] 3. Forced vital capacity as a percentage of predicted value (FVC%) ≥ 60%;
[0134] 4. The disease duration is 2 years or less (starting from the first appearance of any ALS symptoms);
[0135] 5. Aged 45 to 70 (inclusive), regardless of gender;
[0136] 6. Volunteer to participate in this clinical trial, provide informed consent and sign the informed consent form.
[0137] 4-2-2 Exclusion criteria
[0138] 1. Patients diagnosed with familial ALS (based on family history);
[0139] 2. Those with obvious cognitive impairment (MMSE scale: illiterate group ≤19 points, primary school group ≤22 points, junior high school and above group with more than 8 years of education ≤26 points);
[0140] 3. Have obvious difficulty in swallowing;
[0141] 4. Severe renal insufficiency: creatinine clearance <30 mL / min (Cockcroft-Gault formula), or other known severe renal insufficiency;
[0142] 5. Severe liver damage: ALT, AST>3 times the upper limit of normal value, or other known liver diseases such as acute and chronic active hepatitis, cirrhosis, etc.;
[0143] 6. During the screening period, patients with acute myocardial infarction or interventional treatment within the past 6 months, and patients with heart failure (according to NYHA classification, III-IV patients);
[0144] 7. Patients with malignant tumors, serious diseases of blood, digestive system or other systems;
[0145] 8. Allergic constitution;
[0146] 9. Pregnant and lactating women;
[0147] 10. Participated in other clinical trials within 30 days before screening;
[0148] 11. Other situations that the researchers consider unsuitable for inclusion.
[0149] 4-2-3 Treatment Plan
[0150] Patients were enrolled after signing the informed consent and meeting the inclusion / exclusion criteria and received alitoxan therapy on the basis of conventional treatment.
[0151] The patients enrolled in this study received conventional treatment as the basic treatment, and lumbar puncture plus intravenous treatment were given at the same time: they were randomly enrolled after completing the screening within 1 week, and the drug treatment was given by lumbar puncture twice a week. When there was no lumbar puncture, the drug was given intravenously once a day. The treatment dose for lumbar puncture was 130 μg, twice a week, and the intravenous dose was 130 μg (diluted and prepared with 100 ml of normal saline). Follow-up began after the end of treatment, and follow-up was performed once on the 11th day, 6th week, and 8th week, respectively, to collect various safety and efficacy test information.
[0152] 4-2-4 Treatment Effect
[0153] See also Fig.13 The 9 patients' ALSFRS-R scores increased by an average of 1.44 points before and after treatment, and the Norris scores increased by an average of 3.67 points, indicating that Alito can block the course of ALS and show significant improvement.
[0154] See also Fig.14 and Fig.15 After 2 weeks of taking aritol, both ALSFRS-R and Norris scores rebounded; during the 4-week withdrawal period, ALSFRS-R gradually decreased; after 2 weeks of taking the drug again, ALSFRS-R rebounded again. This shows that aritol has a direct effect on the treatment of ALS.
[0155] TDP-43 exists in the form of amyloid in patient cells such as neurons and glial cells and is one of the main pathological hallmark proteins of amyotrophic lateral sclerosis and frontotemporal lobar degeneration and motor neuron disease. Fig.16 After 2 weeks of taking Alitol, the concentration of TDP-43 in the cerebrospinal fluid decreased; during the 4-week withdrawal period, the concentration of TDP-43 in the cerebrospinal fluid rebounded; after taking the drug again for 2 weeks, the concentration of TDP-43 in the cerebrospinal fluid decreased again. This shows that Alitol helps the level of TDP-43 in the cerebrospinal fluid to undergo benign changes during the medication period.
[0156] The TDP-43 concentration in the serum of healthy people (2248pg / ml) is much higher than that of ALS patients, so Hospital A tracked the changes in TDP-43 protein concentrations in the cerebrospinal fluid and serum of 4 patients, as shown in Table 3. During the medication cycle, the patients took the drug for 2 weeks, stopped the drug for 4 weeks, and took the drug again for 2 weeks. It can be found that with the use of Alito, the TDP-43 concentration in the patient's cerebrospinal fluid decreased, and the TDP-43 concentration in the serum increased, showing an overall benign change.
[0157] Table 3 Changes in TDP-43 protein concentration in cerebrospinal fluid and serum of patients
[0158]
[0159] The above is a further detailed description of the present invention, which should not be regarded as a limitation on the specific implementation of the present invention. For ordinary technicians in the technical field to which the present invention belongs, simple deduction or replacement without departing from the concept of the present invention is within the protection scope of the present invention.
Claims
1. A use of a protein polymer in treating amyotrophic lateral sclerosis, characterized in that: The protein polymer is used for reducing the concentration of TDP-43 protein in cerebrospinal fluid and increasing the concentration of TDP-43 protein in serum.
2. The use of the protein polymer according to claim 1 in treating ALS, characterized in that: The protein polymer comprises at least the following proteins: sp|P02768|ALBU_HUMAN Serum albumin OS=Homo sapiens; sp|P02787|TRFE_HUMAN Serotransferrin OS=Homo sapiens.
3. The use of the protein polymer according to claim 2 in treating ALS, characterized in that: The protein polymer also includes at least one of the following proteins: sp|P51884|LUM_HUMAN Lumican OS=Homo sapiens; sp|P62736|ACTA_HUMAN Actin, aortic smooth muscle OS=Homo sapiens; sp|P01009|A1AT_HUMAN Alpha-1-antitrypsin OS=Homo sapiens; sp|P07951|TPM2_HUMAN Tropomyosin beta chain OS=Homo sapiens; sp|P08670|VIME_HUMAN Vimentin OS=Homo sapiens; sp|P02751|FINC_HUMAN Fibronectin OS=Homo sapiens; sp|P09493|TPM1_HUMAN Tropomyosin alpha-1chain OS=Homo sapiens; sp|P21333|FLNA_HUMAN Filamin-A OS=Homo sapiens; sp|P0DOX5|IGG1_HUMAN Immunoglobulin gamma-1heavy chain OS=Homo sapiens; sp|P24821|TENA_HUMAN Tenascin OS=Homo sapiens; sp|P01023|A2MG_HUMAN Alpha-2-macroglobulin OS=Homo sapiens; sp|P60709|ACTB_HUMAN Actin,cytoplasmic 1OS=Homo sapiens; sp|P69891|HBG1_HUMAN Hemoglobin subunit gamma-1OS=Homo sapiens; sp|P01024|C3 HUMAN Complement C3 OS=Homo sapiens.
4. The use of the protein polymer in treating ALS according to claim 3, characterized in that: The sum of the masses of the sp|P02768|ALBU_HUMAN Serum albumin OS=Homo sapiens and the sp|P02787|TRFE_HUMAN Serotransferrin OS=Homo sapiens in the protein polymer accounts for more than 40% of the total mass.
5. Use of the protein polymer according to any one of claims 1 to 4 in treating ALS, characterized in that: The preparation of the protein polymer comprises the following steps: S1: Cultivating mesenchymal stem cells and using ultraviolet irradiation to create a stress environment; S2: Lysing the mesenchymal stem cells, separating and purifying to obtain the protein polymer.
6. The use of the protein polymer in treating ALS according to claim 5, characterized in that: The protein polymer satisfies at least one of the following characteristics: 1) During the molecular sieve exclusion chromatography, under the conditions of the exclusion chromatography with a flow rate of 0.1-0.3 ml / min and the eluent being PBS, the elution volume of the first component peak was 12-13.2 ml, the elution volume of the second component peak was 15.2-17 ml, the elution volume of the third component peak was 17-20 ml, the elution volume of the fourth component peak was 29-31 ml, and the elution volume of the fifth component peak was 31-34 ml; 2) During SDS-PAGE detection, 4-20% precast gel was used for sample separation and detection. The sample bands were mainly distributed in the range of 11KD to 100KD, and the molecular weight was from large to small. The first band was located between 75KD and 100KD; the second band was located between 63KD and 75KD; 3) In reverse phase HPLC detection, the sample volume is 80-120 μL, the column temperature is 20-30° C., the flow rate is 0.2-0.8 mL / min, the detection wavelength is 260 nm and / or 280 nm, the mobile phase is PBS solution, and the peak time after sample separation is between 10 and 40 min, among which the peak time of characteristic peak 1 is 13-17 min, and the peak time of characteristic peak 2 is 20-22 min.
7. The use of the protein polymer in treating ALS according to claim 5, characterized in that: The ultraviolet irradiation time is 1 to 30 hours; And / or, the intensity of the ultraviolet radiation is 10 to 100 μW / cm 2 ; And / or, the wavelength of the ultraviolet light is 290-340 nm.
8. The use of the protein polymer in treating ALS according to claim 5, characterized in that: The culture medium used in the culture is serum-free MSCs culture medium.
9. The use of the protein polymer in treating ALS according to claim 5, characterized in that: The mesenchymal stem cells are selected from one of umbilical cord-derived human mesenchymal stem cells, bone marrow-derived mesenchymal stem cells, and human placenta-derived mesenchymal stem cells.
10. Use of the protein polymer according to any one of claims 1 to 4 in treating ALS, characterized in that: The administration method of the protein polymer is selected from intrathecal administration, intravenous administration, and a combination of intrathecal and intravenous administration.
Citation Information
Patent Citations
High-molecular extract in umbilical cord mesenchymal stem cells, application and detection method
CN113499306A
Neural repair protein composition as well as preparation method and application thereof
CN116555176A
Protein composition for preventing and treating gradual freezing as well as preparation method and application of protein composition
CN118726514A
Improved adipose stem cell-derived secretome therapy for amyotrophic lateral sclerosis and other neurdegenerative disorders
WO2023086260A1
Cited By
Activity analysis and detection method of stress-induced mesenchymal stem cell extract
CN119776483A
Use of protein polymer in treatment of amyotrophic lateral sclerosis
WO2026017017A1
Muse cell-derived protein complex, preparation method therefor, and use thereof
WO2026077393A1
